Showing results (121-130 of 410) with videos related to

Sort By:
Pageof 41
Seminars in Roentgenology|July 24, 2002
Positron emission tomography in thyroid cancer managementSteven M Larson, Richard Robbins
Current Opinion in Urology|December 20, 2007
Advances in positron emission tomography applications for urologic cancersSteven M Larson, Heiko Schöder
Seminars in Nuclear Medicine|October 20, 2004
Positron emission tomography for prostate, bladder, and renal cancerHeiko Schöder, Steven M Larson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumorsMichael J Morris, Neeta Pandit-Taskar, Chaitanya R Divgi, et al.
Pediatric Blood & Cancer|November 9, 2022
Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastomaKathryn R Tringale, Suzanne L Wolden, Dana L Casey, et al.
Journal of Hematology & Oncology|November 12, 2022
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignanciesKim Kramer, Neeta Pandit-Taskar, Brian H Kushner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2011
(124)I-huA33 antibody PET of colorectal cancerJorge A Carrasquillo, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Leukemia & Lymphoma|August 10, 2011
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary diseaseHeather Landau, Neeta Pandit-Taskar, Hani Hassoun, et al.
Health Physics|February 25, 2014
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancerLawrence T Dauer, Matthew J Williamson, John Humm, et al.
Pageof 41